Banerjee R, Hersh AL, Newland J, et al; on behalf of the Emerging Infections Network Hemolytic-Uremic Syndrome Study Group Most (92%) of the cases were confirmed by culture with the remaining 8% being ...

Please provide your email address to receive an email when new articles are posted on . Researchers reviewed the efficacy of ravulizumab based on 2-year data from two phase 3, single-arm studies. eGFR ...

Atypical haemolytic uremic syndrome (aHUS) is an uncommon, yet potentially life‐threatening disorder predominantly characterised by dysregulation of the alternative complement pathway. Unlike the more ...

Background. Antibiotic administration to individuals with Shiga toxin–producing Escherichia coli (STEC) infection remains controversial. We assessed if antibiotic administration to individuals with ...

(RTTNews) - Alexion Pharmaceuticals Inc. (ALXN) said Friday that Japan has approved Ultomiris or ravulizumab for adults and children living with atypical hemolytic uremic syndrome or aHUS. atypical ...

The “fast-moving” E. coli outbreak the Centers for Disease Control and Prevention (CDC) warned of earlier this month has escalated, as 38 people have reportedly been hospitalized. Additionally, eight ...

The Key Atypical Hemolytic Uremic Syndrome Companies in the market include - Alexion Pharmaceuticals, Hoffmann-La Roche, Novartis, NovelMed Therapeutics, and others. The Atypical Hemolytic Uremic ...

In Belgium, it is mandatory to report Shiga toxin-producing Escherichia coli (STEC) infections to the health inspection authorities. To facilitate the decision making regarding infection control ...

Coffman is a writer, actor, and multi-hyphenate creative. In 2022, I gave birth to a healthy baby girl and triggered a wildly violent chain of events: multiple organ failure, hemorrhaging, blood clots ...

Atypical Haemolytic Uremic Syndrome is an ultra-rare disorder that affects only about one in two million people each year. The condition occurs when part of the body’s immune system—known as the ...